APA (7th ed.) Citation

PW, W., PD, B., JV, P., PL, B., LA, L., CL, D., . . . W, A. (2022). Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO precision oncology, 6, e2100463. https://doi.org/10.1200/PO.21.00463

Chicago Style (17th ed.) Citation

PW, Whitworth, et al. "Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature." JCO Precision Oncology 6 (2022): e2100463. https://doi.org/10.1200/PO.21.00463.

MLA (9th ed.) Citation

PW, Whitworth, et al. "Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature." JCO Precision Oncology, vol. 6, 2022, p. e2100463, https://doi.org/10.1200/PO.21.00463.